Lupus & antiphospholipid syndrome
Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus: A meta-analysis
Authors' conclusion
PAH is a serious complication of SLE.
Study context
- Population
- Patients with Systemic Lupus Erythematosus (SLE); Medline, Embase, Web of Science and Cochrane Library searched up to April 11, 202319 articles
- Comparison
- Potential risk factors present vs absent for pulmonary arterial hypertension (PAH) in SLE
- Outcome
- PAH related to SLE
Methodological detailsunivariate and multivariate meta-regression, sensitivity analyses, risk of bias by Newcastle-Ottawa Scale (NOS)
- Univariate and multivariate meta-regression
- Sensitivity analyses
- Risk of bias by NOS
Pooled result
As reported in the abstract
Risk factors for PAH related to SLE (pooled RR)
Relative risk (95% CI)P value
Female gender
1.04(1.02–1.06)
P = 0.0001ILD
4.36(2.42–7.85)
P = 0.0001Alopecia
1.39(1.06–1.83)
P = 0.017RP
1.83(1.41–2.37)
P = 0.0001Systemic hypertension
1.30(1.07–1.58)
P = 0.007Serositis
2.29(1.89–2.77)
P = 0.0001Pericardial effusion
3.33(2.20–5.05)
P = 0.0001Anti-RNP
1.86(1.19–2.91)
P = 0.006Anti-SSA
1.28(1.01–1.62)
P = 0.041Anti-SSB
1.38(1.19–1.60)
P = 0.0001Anti-U1RNP
1.58(1.07–2.34)
P = 0.023Thrombocytopenia
1.38(1.14–1.68)
P = 0.001Current smokers
2.20(1.19–4.06)
P = 0.012Original publication
Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus: A meta-analysis. Lupus. Published 12 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →